Algorithms for the diagnosis and treatment of restless legs syndrome in primary careNovel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF featuresLevodopa for the treatment of restless legs syndromeDopamine agonists for the treatment of restless legs syndromeA mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson diseaseNiemann-Pick C disease gene mutations and age-related neurodegenerative disordersGenome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1Impairment of brainstem implicit learning paradigms differentiates multiple system atrophy (MSA) from idiopathic Parkinson syndromeMonitoring of 30 marker candidates in early Parkinson disease as progression markers.Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.Functional neuroimaging studies in restless legs syndrome.One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementiaThe tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response.Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.Blood cis-eQTL analysis fails to identify novel association signals among sub-threshold candidates from genome-wide association studies in restless legs syndrome.Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patchLewy body and parkinsonian dementia: common, but often misdiagnosed conditions.Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale.Targeted resequencing and systematic in vivo functional testing identifies rare variants in MEIS1 as significant contributors to restless legs syndrome.The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia.Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.Sex and the risk of restless legs syndrome in the general population.Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome.Restless legs syndrome-current therapies and management of augmentation.Review of diagnostic instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations.Review of quality of life instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendationsPractice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine.Family-based association study of the restless legs syndrome loci 2 and 3 in a European population.Restless legs syndrome and periodic limb movements.Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions.Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome.Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
P50
Q21261396-432C8E57-35C3-42D1-BEAE-6709686025A2Q21261404-7B24547D-0BB4-41CF-B9F1-D4E6656FD40FQ24234185-65CEE65D-0887-4138-ABD9-036D690AF44DQ24235988-9C0B3CD8-C87B-4924-A3DC-098CDFA6266CQ24633417-BC41CFF0-C998-49C4-9A89-B354BF61503DQ28538079-9DE2A34A-90D4-474E-A0B5-194E91CAF4A9Q28943488-7EC4D765-4E31-4DCC-B9FB-9B44AF8299C3Q30544858-BD5828B6-981A-41EF-8105-33D391FC8196Q30783504-4A81C466-252E-4EB4-AA3E-4FC19F4D5865Q30816299-2B93D5A0-737F-44B4-8B4C-6C268FC5B682Q30940165-79C7BAD0-74A6-43E3-A105-5F871E96F4D1Q33156589-E3BBC84F-6F0F-43E1-BD53-A7541C541CA8Q33239180-CFCCDD27-1497-43EA-95FA-7728B6331B89Q33350218-D4CC4267-2D47-4721-8EF4-D82AF87297AEQ33591471-BB367F03-4DD6-4A23-8720-01070329215EQ33685725-F5C09A2D-A3EF-4245-B856-2D2F53C2E56DQ33709637-3B01A76A-7652-44FC-BDC8-3326EDAA79C0Q33724257-F2DCEA02-9CFE-46FE-9F9B-C7C527148570Q33764504-25D7DD41-E111-43D9-BFA5-477BF5AA15F5Q33766006-E0D20843-6660-4F95-9E54-30CF41ECEC02Q33858791-BA813193-8A9E-4B51-A52C-50170100DA67Q33909482-22EEAA1C-7182-4E2D-BDD6-58023D7ACE60Q34034076-A15CCD4F-5854-46C9-BA6C-64C985D12F5DQ34123736-B635904C-C96F-4ED2-8942-0D289C71BA7BQ34273561-E11D0B1E-F9D4-428A-9475-056369A6AC4EQ34292722-2EDA7B86-457F-44AA-84EB-053C190A6F66Q34445954-59F80AC7-86E7-4EAA-B2B1-E5ECCCF30C98Q34487111-5625A4E4-249B-417C-9885-1B8250104B41Q34542952-DF3E8315-FD71-4787-903D-7C4A9EF43F2DQ34542958-9EC6B906-A355-4655-8A97-794217B6E528Q34544928-005A1AC5-18DF-44F6-953A-0AE1A2A8850DQ34556476-1FE8AE9C-9835-4E6E-A5A8-891093911574Q34585382-9984CA98-F692-4436-8014-9E64A2B7BBBCQ34585600-8C3A3D2A-164D-499B-94B4-148D519EB4F6Q34610327-80FD168F-C770-4903-AE8B-4087EAA3A8E6Q34619534-76E2AAA7-679A-46D1-A407-77DA9FE48E45Q34648414-B43DF3FC-C57C-4EAD-873A-5AE75346BC4CQ34653028-7EC00546-3FF7-4772-8FAC-68E678506F4FQ34721859-A40C680D-79BA-4349-B6B8-FA1FD6B1EAE0Q34771200-67571C28-4198-45A5-A538-5F45B6D6958E
P50
description
deutsche Neurologin
@de
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Claudia Trenkwalder
@ast
Claudia Trenkwalder
@de
Claudia Trenkwalder
@en
Claudia Trenkwalder
@es
Claudia Trenkwalder
@nl
Claudia Trenkwalder
@sl
type
label
Claudia Trenkwalder
@ast
Claudia Trenkwalder
@de
Claudia Trenkwalder
@en
Claudia Trenkwalder
@es
Claudia Trenkwalder
@nl
Claudia Trenkwalder
@sl
prefLabel
Claudia Trenkwalder
@ast
Claudia Trenkwalder
@de
Claudia Trenkwalder
@en
Claudia Trenkwalder
@es
Claudia Trenkwalder
@nl
Claudia Trenkwalder
@sl
P214
P227
P106
P19
P21
P213
0000 0004 0142 0541
P214
P227
P31
P569
1959-01-01T00:00:00Z
P735
P7859
viaf-210377687